Heron Therapeutics Inc
AXD2
Company Profile
Business description
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Contact
100 Regency Forect Drive
Suite 300
CaryNC27518
USAT: +1 858 251-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
122
Stocks News & Analysis
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
stocks
Is it time to bail on Australian stocks?
Is your home bias costing your portfolio better returns?
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,874.50 | 25.20 | 0.28% |
| CAC 40 | 8,140.59 | 50.31 | 0.62% |
| DAX 40 | 25,537.75 | 135.47 | 0.53% |
| Dow JONES (US) | 52,049.40 | 43.71 | -0.08% |
| FTSE 100 | 10,688.47 | 30.34 | 0.28% |
| HKSE | 24,713.78 | 46.54 | 0.19% |
| NASDAQ | 26,165.05 | 183.48 | 0.71% |
| Nikkei 225 | 63,923.00 | 438.90 | 0.69% |
| NZX 50 Index | 13,622.72 | 138.50 | 1.03% |
| S&P 500 | 7,608.83 | 23.10 | 0.30% |
| S&P/ASX 200 | 8,696.50 | 24.00 | 0.28% |
| SSE Composite Index | 3,891.60 | 27.32 | 0.71% |